{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:49:28Z","timestamp":1794487768325,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13018-018-0865-3","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T11:19:15Z","timestamp":1533208755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis"],"prefix":"10.1186","volume":"13","author":[{"given":"Jiaqi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"5","key":"865_CR1","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","volume":"25","author":"ES Siris","year":"2014","unstructured":"Siris ES, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25(5):1439\u201343.","journal-title":"Osteoporos Int"},{"issue":"4","key":"865_CR2","first-page":"203","volume":"106","author":"W Liu","year":"2015","unstructured":"Liu W, et al. Meta-analysis of osteoporosis: fracture risks, medication and treatment. Minerva Med. 2015;106(4):203\u201314.","journal-title":"Minerva Med"},{"key":"865_CR3","doi-asserted-by":"publisher","unstructured":"Maghbooli Z, et al. Negative correlation of high-density of lipoprotein-cholesterol and bone mineral density in postmenopausal Iranian women with vitamin D deficiency. Menopause. 2018. \n                    https:\/\/doi.org\/10.1097\/GME.0000000000001082\n                    \n                  .","DOI":"10.1097\/GME.0000000000001082"},{"issue":"1","key":"865_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11657-018-0443-7","volume":"13","author":"S Fujiwara","year":"2018","unstructured":"Fujiwara S, et al. Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review. Arch Osteoporos. 2018;13(1):34.","journal-title":"Arch Osteoporos"},{"key":"865_CR5","doi-asserted-by":"publisher","unstructured":"Buerba RA, et al. Bisphosphonate and Teriparatide use in thoracolumbar spinal fusion: a systematic review and meta-analysis of comparative studies. Spine (Phila Pa 1976). 2018. \n                    https:\/\/doi.org\/10.1097\/BRS.0000000000002608\n                    \n                  .","DOI":"10.1097\/BRS.0000000000002608"},{"issue":"12","key":"865_CR6","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00198-017-4175-0","volume":"28","author":"T Saito","year":"2017","unstructured":"Saito T, et al. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int. 2017;28(12):3289\u2013300.","journal-title":"Osteoporos Int"},{"issue":"4","key":"865_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","volume":"66","author":"T Lin","year":"2012","unstructured":"Lin T, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract. 2012;66(4):399\u2013408.","journal-title":"Int J Clin Pract"},{"key":"865_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.","journal-title":"Bmj"},{"issue":"9","key":"865_CR9","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","volume":"27","author":"C Beaudoin","year":"2016","unstructured":"Beaudoin C, et al. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016;27(9):2835\u201344.","journal-title":"Osteoporos Int"},{"key":"865_CR10","doi-asserted-by":"crossref","unstructured":"Lou S, et al. Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials. BMJ Open. 2018;8(3):e015187.","DOI":"10.1136\/bmjopen-2016-015187"},{"issue":"3","key":"865_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jocd.2008.04.001","volume":"11","author":"TJ Beck","year":"2008","unstructured":"Beck TJ, et al. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom. 2008;11(3):351\u20139.","journal-title":"J Clin Densitom"},{"issue":"12","key":"865_CR12","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"EM Lewiecki","year":"2007","unstructured":"Lewiecki EM, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832\u201341.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"865_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"865_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153\u201361.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"865_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72\u201381.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"865_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, et al. Final results of the DAPS (Denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317\u201326.","journal-title":"Osteoporos Int"},{"issue":"6","key":"865_CR17","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","volume":"22","author":"DL Kendler","year":"2011","unstructured":"Kendler DL, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22(6):1725\u201335.","journal-title":"Osteoporos Int"},{"issue":"6","key":"865_CR18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291\u20139.","journal-title":"Obstet Gynecol"},{"key":"865_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48\u201354.","journal-title":"Bone"},{"issue":"8","key":"865_CR20","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, et al. Denosumab or Zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101(8):3163\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"865_CR21","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886\u201394.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"865_CR22","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","volume":"97","author":"MH Murad","year":"2012","unstructured":"Murad MH, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1871\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"865_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-0-387-72009-8_18","volume":"602","author":"M Stolina","year":"2007","unstructured":"Stolina M, et al. RANKL inhibition: from mice to men (and women). Adv Exp Med Biol. 2007;602:143\u201350.","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"865_CR24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059\u201366.","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-018-0865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13018-018-0865-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-018-0865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T23:15:18Z","timestamp":1564701318000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-018-0865-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1186\/s13018-018-0865-3","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a meta-analysis; no relative problems exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"194"}}